Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other financing activities (2020 - 2024)

Historic Other financing activities for Keros Therapeutics (KROS) over the last 4 years, with Q3 2024 value amounting to $130000.0.

  • Keros Therapeutics' Other financing activities rose 38148.15% to $130000.0 in Q3 2024 from the same period last year, while for Sep 2025 it was $197000.0, marking a year-over-year decrease of 3919.75%. This contributed to the annual value of $171000.0 for FY2024, which is 8191.49% up from last year.
  • Latest data reveals that Keros Therapeutics reported Other financing activities of $130000.0 as of Q3 2024, which was up 38148.15% from $67000.0 recorded in Q4 2023.
  • Over the past 5 years, Keros Therapeutics' Other financing activities peaked at $219000.0 during Q1 2020, and registered a low of $8000.0 during Q2 2020.
  • Moreover, its 4-year median value for Other financing activities was $100000.0 (2021), whereas its average is $106285.7.
  • Per our database at Business Quant, Keros Therapeutics' Other financing activities plummeted by 4818.65% in 2021 and then surged by 38148.15% in 2024.
  • Quarter analysis of 4 years shows Keros Therapeutics' Other financing activities stood at $193000.0 in 2020, then plummeted by 48.19% to $100000.0 in 2021, then tumbled by 33.0% to $67000.0 in 2023, then surged by 94.03% to $130000.0 in 2024.
  • Its Other financing activities stands at $130000.0 for Q3 2024, versus $67000.0 for Q4 2023 and $27000.0 for Q3 2023.